E. Diamandidou

Front-line Bevacizumab in combination with Oxaliplatin, Leucovorin and 5-Fluorouracil (FOLFOX) in patients with metastatic colorectal cancer: a multicenter phase II study

D. Mavroudis, V. Georgoulias, S. Agelaki, 2007, BMC Cancer.

Two-phase study of hepatic artery vascular occlusion with microencapsulated cisplatin in patients with liver metastases from neuroendocrine tumors.

J. Ajani, S. Wallace, D. Yang, 1998, AJR. American journal of roentgenology.

Mycosis fungoides and Sezary syndrome.

Philip R. Cohen, R. Kurzrock, E. Diamandidou, 1996, Blood.

Transformation of mycosis fungoides/Sezary syndrome: clinical characteristics and prognosis.

R. Kurzrock, L. Fayad, M. Duvic, 1998, Blood.

Prognostic factor analysis in mycosis fungoides/Sézary syndrome.

R. Kurzrock, L. Fayad, M. Duvic, 1999, Journal of the American Academy of Dermatology.

Preliminary experience with bevacizumab in combination with standard chemotherapeutic regimens in the treatment of non-small cell lung cancer: a retrospective study.

C. Emmanouilides, E. Diamandidou, E. Sapountzi, 2008, Hematology/oncology and stem cell therapy.

Treatment-related leukemia in breast cancer patients treated with fluorouracil-doxorubicin-cyclophosphamide combination adjuvant chemotherapy: the University of Texas M.D. Anderson Cancer Center experience.

G. Hortobagyi, A. Buzdar, D. Frye, 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Mycosis fungoides and Sezary syndrome.

R. Kurzrock, E. Diamandidou, Philip R. Cohen, 1996, Blood.

Mycosis fungoides and Sezary syndrome.

R. Kurzrock, B. Espinet, R. Salgado, 1996, Blood.